TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05176119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Injection
Description: At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
Study: NCT05827939

Intervention type: OTHER
Intervention: Covid19 Vaccination dose
Description: Participants above or below 2 dose Covid19 Vaccination

Intervention type: OTHER
Intervention: Covid19 Vaccination dose
Description: Participants above or below 2 dose Covid19 Vaccination

Intervention type: OTHER
Intervention: Covid19 Vaccination dose
Description: Participants above or below 2 dose Covid19 Vaccination
Study: NCT06407037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the prone position. 30 ml of 0.25% bupivacaine will be used in applications.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Posterior Superior Intercostal Plane Block
Description: Serratus Posterior Superior Intercostal Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the prone position. 30 ml of 0.25% bupivacaine will be used in applications.
Study: NCT04624711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
Study: NCT05085639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5130
Description: GLS-5310 DNA plasmid vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5130
Description: GLS-5310 DNA plasmid vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5130
Description: GLS-5310 DNA plasmid vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04782271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium Low dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium Low dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium Middle dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium Middle dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium High dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium High dose q.d
Description: 1 drop in the randomized eye once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium High dose b.i.d
Description: 1 drop in the randomized eye twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL18001 sodium High dose b.i.d
Description: 1 drop in the randomized eye twice daily
Study: NCT05959135

Intervention type: DEVICE
Intervention: Gastric ultrasonography
Description: It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies

Intervention type: DEVICE
Intervention: Gastric ultrasonography
Description: It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies
Study: NCT04817644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide once daily for a total of 10 days
Study: NCT05234970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wysa
Description: Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Harvard College App
Description: Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
Study: NCT04933851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT1VATE
Description: ACT1VATE, informed by Acceptance and Commitment Therapy (ACT), will consist of five, 90-minute group-based telemedicine therapy sessions delivered by a Behavioral Health Provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSME/S
Description: Diabetes self-management education and support (DSME/S) will be delivered by a Certified Diabetes Care and Education Specialist via one-on-one telemedicine format.
Study: NCT06097117

Intervention type: DIAGNOSTIC_TEST
Intervention: MultiplexPCR
Description: PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.
Study: NCT05217745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MLCT Oil
Description: 1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LCT Oil (Corn Oil)
Description: 1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
Study: NCT05376826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Led Physical Therapy
Description: Nurse Led Physical Therapy in Form of Range of Motion Exercises
Study: NCT04821037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy
Study: NCT06119490

Intervention type: DRUG
Group type: OTHER
Intervention: Abrocitinib
Description: Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Tofacitinib
Description: Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
Study: NCT05576389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Fluzoparib
Description: Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
Study: NCT06324006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIB-01
Description: LIB-01 oral suspension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension
Study: NCT04035070

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: co-amoxiclav-clindamycin solution
Description: antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTAD
Description: mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% sodium hypochlorite
Description: It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
Study: NCT05074264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - Anal
Description: Undergo collection of anal swabs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - Cervical
Description: Undergo collection of cervical swabs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Undergo colposcopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Anoscopy
Description: Undergo high-resolution anoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo cervical imaging
Study: NCT05739786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liq nitrogen
Description: In Group A patients were subjected to liquid nitrogen cryotherapy (-196 0C) for 3 sessions at every 3 weeks interval. Effectiveness in was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intralesional vitamin D3
Description: Group B were subjected to vitamin D3 (5mg/ml) for 3 sessions at every 3 weeks interval. Effectiveness was ascertained in terms of \> 50% reduction in wart size by an expert dermatologist on physical examination at the end of third session. Patients were followed for further 6 weeks after last session to look for any sort of recurrence and remission.
Study: NCT04640610

Intervention type: OTHER
Intervention: Storage of operating waste
Description: Storage of operating waste of adenoidectomy / tonsillectomy
Study: NCT05809414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule
Description: It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule
Description: It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical.
Study: NCT04972396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Taken by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol and Levonorgestrel
Description: Taken by mouth (PO)
Study: NCT05606367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-slip Balloon Catheter of Shanghai MicroPort Rhythm
Description: The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NSE Coronary Dilatation Catheter
Description: The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
Study: NCT05382832

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-experimental treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-placebo

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: SCS
Description: SCS-placebo
Study: NCT05775640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: serious game
Description: The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
Study: NCT06287970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Auricular Vagus Nerve Stimulation
Description: In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
Study: NCT04738812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified TB treatment (initial phase)
Description: 8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WHO standard TB treatment (initial phase)
Description: 8 weeks of RHEZ with FDC.
Study: NCT05654597

Intervention type: OTHER
Intervention: CAPTURE tool
Description: CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.

Intervention type: OTHER
Intervention: Spirometry
Description: Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
Study: NCT05883462

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Airiver Nasal Drug Coated Balloon (DCB) Catheter.
Description: The balloon is coated with a paclitaxel drug (3.5ug/mm2).
Study: NCT06218095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation application
Description: Teaching the risk of thromboembolism during pregnancy and postpartum through simulation
Study: NCT06051682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence
Description: Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency physician
Description: the emergency physician analyzes the x-rays

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Emergency physician
Description: the emergency physician analyzes the x-rays
Study: NCT04501770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chort 1 of M802
Description: Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 μg, and the maintenance dose during core treatment period and extended treatment period is 5 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chort 2 of M802
Description: Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 μg, and the maintenance dose during core treatment period and extended treatment period is 10 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 of M802
Description: Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 μg, and the maintenance dose during core treatment period and extended treatment period is 20 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 of M802
Description: Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 of M802
Description: Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6 of M802
Description: Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 150 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7 of M802
Description: Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 μg, and on D8, D15, D22 is 225 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 8 of M802
Description: Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.